Last edition
News about "Kilitch Drugs (India) Limited, a BSE and NSE-liste"
Kilitch Drugs to Raise INR 49.92 Cr via Rights Issue to Fund Greenfield Expansion and Growth Plans
At its recent board meeting, the company approved the issuance of 1,398,463 fully paid-up equity shares at INR 357 per share (face value INR 10 and premium of INR 347). The entitlement ratio for eligible shareholders is 2 rights equity shares for every 23 fully paid equity shares held.
Kilitch Drugs (India) Limited, A BSE And NSE-liste | 24/07/2025 | By Darshana | 274
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy